Scripps to work with ImpediMed on cardio validation study

Scripps Green Hospital--Courtesy of Scripps Health

Scripps Health will be using ImpediMed’s SOZO device in a validation study. The study will monitor patients with heart failure who are being tracked via pulmonary artery pressure monitoring.

SOZO is a device that can be used to measure body composition, fluid status and hydration management. The device looks similar to a scale, and features a large touch screen that offers up long-term data on multiple health measurements.

According to a video, SOZO is “a precision device that gives you a detailed picture of your health at a cellular level.” The video also explained that SOZO uses 256 “interactive sensor data points” to offer a detailed view of an individual’s health.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The study will be led by J. Thomas Heywood of the heart failure recovery and research program at Scripps Health and Andrew Accardi, chairman of emergency medicine at Scripps Health. Heywood’s patients from Scripps Green Hospital will be recruited for the study.  

- here's the press release about the partnership
- and here's the release about SOZO

Related Articles:
Aussie ImpediMed raises $57M just after U.S. launch of early Dx tool for lymphedema in cancer
Mayo Clinic, ImpediMed team for better disease monitoring tech

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.